GLP-1 medications such as semaglutide (Ozempic, Wegovy) may reduce alcohol cravings and heavy drinking in some people, according to a small but growing number of clinical trials. However, these medications are not FDA-approved to treat alcohol use disorder (AUD), and researchers are still working out who might benefit, at what dose, and for how long.
Interest has grown quickly as millions of Americans have started GLP-1 medications for diabetes and weight loss, and some have noticed they no longer want their usual drink. The PBS documentary GLP-1s: Reshaping America explores how these drugs are changing health care well beyond their original purpose. For people in recovery and the families supporting them, the question is a natural one: could a weekly injection make cravings easier to manage?
This article explains what GLP-1 medications are, what the research shows about alcohol and drug cravings, and why established addiction treatment remains the most reliable path to recovery. Peak Path Health, in the Hollywood Hills and Woodland Hills of Los Angeles, California, offers evidence-based addiction treatment for adults seeking help with alcohol use and related challenges.
What Are GLP-1 Medications?
GLP-1 medications are glucagon-like peptide-1 receptor agonists. They mimic a natural gut hormone that helps regulate blood sugar, slows digestion, and signals fullness to the brain.
Semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide, and tirzepatide are FDA-approved for type 2 diabetes, chronic weight management, and certain related conditions, depending on the product. Tirzepatide acts on GLP-1 and on a second hormone called GIP. None of these medications is approved to treat addiction.
Because GLP-1 receptors are also found in brain regions involved in reward and motivation, researchers began asking whether these medications might affect more than appetite.
What Does Research Show About GLP-1s and Alcohol Cravings?
Research on GLP-1 medications and alcohol has moved from animal studies to early human trials. The results are encouraging but not yet conclusive.
According to the National Institute on Drug Abuse (NIDA), alcohol and other substances activate the brain’s reward circuitry by increasing dopamine, which reinforces continued use. In animal studies, activating GLP-1 receptors has reduced alcohol-related dopamine release and lowered alcohol intake.
Researchers believe GLP-1 medications may “turn down the volume” on alcohol’s rewarding effects, making a drink feel less appealing. This mechanism is not fully established in humans, and it does not address the emotional, psychological, and environmental factors that drive addiction.
Several clinical trials have tested GLP-1 medications in people with AUD:
- Semaglutide injections (2025): A trial published in JAMA Psychiatry gave 48 adults with AUD who were not seeking treatment low-dose weekly semaglutide or a placebo for nine weeks. The semaglutide group reported less craving, fewer drinks on drinking days, and fewer heavy drinking days, and drank less during a supervised laboratory session.
- Oral semaglutide (2026): A trial of 50 adults with moderate to severe AUD, published in the American Journal of Psychiatry, found that eight weeks of oral semaglutide significantly reduced heavy drinking days compared with placebo. It did not significantly reduce laboratory-measured craving or overall drinks per day.
- Longer-term semaglutide (2026): A 26-week placebo-controlled trial published in The Lancet reported fewer heavy drinking days among adults with both AUD and obesity.
- Exenatide (2022): An earlier trial of exenatide, an older GLP-1 medication, found no overall reduction in heavy drinking days, though participants with obesity appeared to drink less.
Large observational studies have pointed in a similar direction. A 2025 Swedish study of people with AUD found that they had a lower risk of alcohol-related hospitalization during periods when they were taking semaglutide or liraglutide than when they were not.
These findings are promising, but they come with real caveats:
- Most trials have been small and lasted only weeks or months
- Some studies focused on specific groups, such as people with obesity or people not seeking treatment
- Results have been mixed across different measures, such as craving versus heavy drinking
- Observational studies can show associations but cannot prove cause and effect
- Long-term safety and effectiveness for AUD have not been established
Drinking less during a study is also not the same as sustained recovery. Larger, longer trials are needed before GLP-1 medications could be considered a treatment for alcohol use disorder.
Can GLP-1 Medications Reduce Drug Cravings?
Researchers are also studying whether GLP-1 medications affect cravings for other substances. Animal studies have examined cocaine, opioids, and nicotine, and some have shown reduced drug-seeking behavior.
Human evidence is much more limited. In the 2025 semaglutide trial, participants who smoked cut back on cigarettes more than those taking placebo. In the 2026 oral semaglutide trial, an exploratory analysis of 11 participants who used cannabis suggested fewer days of cannabis use. These are small, early signals, not proof of benefit.
Each substance affects the brain differently, so findings for alcohol cannot be automatically applied to opioids, stimulants, or other drugs. No GLP-1 medication has been shown to treat any drug use disorder.
Are GLP-1 Medications Approved to Treat Addiction?
No. GLP-1 medications are not FDA-approved to treat alcohol use disorder or any other substance use disorder. Some physicians may prescribe them off-label, but off-label use is an individual clinical decision and does not establish that a medication is effective for addiction.
Proven medications already exist. The FDA has approved naltrexone, acamprosate, and disulfiram for alcohol use disorder, and buprenorphine, methadone, and naltrexone for opioid use disorder. According to the National Institute on Alcohol Abuse and Alcoholism (NIAAA), medications for AUD are effective but underused. GLP-1 medications should not be viewed as a substitute for these treatments.
Anyone currently in treatment should not stop, start, or change medications based on emerging research without speaking to their care team.
What Safety Considerations Should Someone Discuss With a Doctor?
GLP-1 medications can cause side effects and are not appropriate for everyone. Common side effects include nausea, vomiting, diarrhea, and constipation. According to FDA prescribing information, more serious risks include pancreatitis and gallbladder problems. These medications also carry a boxed warning about thyroid C-cell tumors, and they should not be used by people with certain personal or family medical histories.
People with a history of heavy drinking should also discuss:
- Low blood sugar: Alcohol can lower blood sugar, especially in people also taking insulin or other diabetes medications.
- Dehydration: Vomiting and diarrhea from GLP-1 medications, combined with alcohol, can increase the risk of dehydration and kidney strain.
- Nutrition: Reduced appetite can make it harder to recover from nutritional deficiencies that are common with long-term alcohol use.
- Unregulated products: The FDA has warned about compounded and unapproved GLP-1 products, including dosing errors. These medications should only come from a licensed prescriber and pharmacy.
Why Does Comprehensive Addiction Treatment Still Matter?
Cravings are a common challenge in recovery, but they are only one part of addiction. Recovery typically involves addressing physical health, mental health, relationships, coping skills, and the environments that shape substance use. Even if GLP-1 medications eventually prove useful, researchers expect they would serve as one component of a broader treatment plan, not a replacement for it.
According to NIDA’s Principles of Drug Addiction Treatment, effective programs combine behavioral therapies, medical care, and ongoing support tailored to each person’s needs. Alcohol and drug use disorders also frequently occur alongside mental health conditions such as anxiety, depression, and trauma, and treatment that addresses both tends to produce better outcomes.
Peak Path Health provides dual diagnosis treatment that combines evidence-based therapies with holistic approaches. Therapies include cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), and eye movement desensitization and reprocessing (EMDR). Holistic options include yoga, nutrition therapy, and acupuncture. Clients can discuss medication options, including FDA-approved medications for alcohol use disorder, with the clinical team as part of an individualized plan.
GLP-1 and Alcohol FAQs
No. Ozempic (semaglutide) is not FDA-approved to treat alcoholism or alcohol use disorder. It is approved for adults with type 2 diabetes, including to lower certain heart and kidney risks.
Yes. Anyone curious about this research can raise it with their healthcare provider, who can review their full medical history, current medications, and FDA-approved treatment options for AUD.
Anyone taking a GLP-1 medication should discuss alcohol use with their prescriber. Alcohol can affect blood sugar and may worsen digestive side effects or dehydration.
People experiencing alcohol cravings can speak with a healthcare provider, contact a treatment center, or call SAMHSA’s National Helpline at 1-800-662-4357. The helpline is free, confidential, and available 24/7.
Explore Addiction Treatment Options at Peak Path Health
New research on GLP-1 medications offers hope, but evidence-based treatment remains the foundation of recovery. Peak Path Health, in the Hollywood Hills and Woodland Hills of Los Angeles, California, offers medical detox, inpatient treatment, and dual diagnosis care for adults seeking help with alcohol and other substances. The facility is LegitScript certified.
Every client receives an individualized care plan that addresses both addiction and co-occurring mental health conditions. Contact Peak Path Health today to begin your personalized recovery journey.
